NCT00471380 - A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2008

Conditions

GlaucomaOcular Hypertension

Interventions

DRUG

travoprost 0.004% and brinzolamide 1%

Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)

DRUG

fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle

group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).

Trial Locations (1)

95123

Catania, Catania